Decipher is now part of Veracyte!     Learn More
Decipher is now part of Veracyte!     Learn More
Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
New findings presented at ATS 2021 Conference also suggest novel test can be successfully enabled on nCounter Analysis System to support international expansion SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced that data reinforcing the
View HTML
Toggle Summary Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta ® Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used
View HTML

Events

There are currently no events to display.

Presentations

Title Documents

Corporate Presentation April 2021